UBCNews - Business - Inside Kure HealthEcosystem Fund: Why Veracor Built Healthcare Companies First

Episode Date: March 25, 2026

Welcome back to the show. Today we're examining a strategy that flips traditional private equity on its head. Most funds raise capital first, then hunt for deals. But what if you built the companies for twenty years, proved they work, and then launched the fund? Veracor Capital City: Miami Address: 1395 Brickell Avenue Website: https://veracorcapital.com/

Welcome back to the show. Today, we're examining a strategy that flips traditional private equity on its head. Most funds raise capital first, then hunt for deals. But what if you built the companies for 20 years, prove they work, and then launched the fund? Right, and that's exactly what happened here. Instead of promising investors a pipeline, they showed up with operational infrastructure already in place, clinical data in hand, and a methodology that's been treating real patients. So let's set the stage. We're talking about a $250 million fund focused on something called signal-based medicine. What does that actually mean for someone listening who's not deep in the health care world? Signal-based medicine is a clinical approach that identifies and corrects biological dysfunction at its source at the cellular level. Think about traditional medicine.

It often manages symptoms, keeps patients on recurring treatments. This approach aims to restore function and produce lasting outcome. Mm-hmm. I see. And they claim a 95% success rate with over 47,000 patients treated. That's not a small sample size. Exactly. 20 years of clinical refinement went into developing that methodology. The fund didn't start by asking what might work. It started by scaling what already does work. Build first, then fund. That's the core assertion. So, um, who's behind this? Because the veteran-owned angle is, prominent in the messaging. Kenton Gray, a Marine Corps veteran and health care entrepreneur, is the founder and managing partner. He's also the creator of signal-based medicine. The firm is veteran-operated with serious clinical credibility. And it's part of a larger ecosystem, right? There

are multiple entities working together. Yeah, the Cure Health ecosystem is a vertically integrated platform delivering signal-based medicine across clinical, consumer, and AI divisions. Rejuvian Health specializes in advanced regenerative medicine focused on cellular healing. Kenton Gray is the founder and architect who built this entire ecosystem over two decades. So investors aren't just buying into a fund. They're getting access to proprietary deal flow, proven clinical methods, and infrastructure that's already live across all 50 states. That's the edge.

Vertical integration means control across the value chain. Regulatory compliance is already in place. The intellectual property is proprietary, and founder capital is invested alongside limited partners, so interests are aligned. That point about proprietary infrastructure sets up our next piece, how they're prioritizing women-led health care ventures. But first, a quick word from our sponsor.

This episode is brought to you by Veracore Capital, a veteran-owned AI-first health care private equity firm. They deploy capital into companies that heal patients, not just manage symptoms. With documented clinical outcomes and operational infrastructure already in place, they offer accredited investors' access to proven methodologies and proprietary deal flow. Learn more at vericorcapital.com. Picking up on proprietary infrastructure, why focus on women-led health care ventures specifically? It's an undervalued sector with significant growth potential.

women-led ventures often face funding gaps despite strong fundamentals. By prioritizing them, the fund taps into overlooked opportunities while driving impact. Makes sense. Now, let's talk about signal-based medicine and that 95% success rate. How do you achieve that kind of consistency? It comes down to three things. First, identifying dysfunction at the cellular level, not just treating surface symptoms. Second, 20 years of clinical data refining protocols.

Third, a vertically integrated platform that controls quality across the patient experience. So you're saying the companies in the portfolio don't optimize for recurring revenue. They optimize for actual recovery. Definitely. Traditional health care often keeps patients dependent on ongoing treatment because that's where recurring revenue lives. This model invests in companies that restore function. The thesis is that the best long-term returns come from healing patients, period. Or as I like to say, cure the patient, not the cash flow. Huh, I like that.

And that's a philosophical shift, but also a financial one. If you heal someone, they're not a recurring customer. Right. But the reputational capital, the clinical validation, and the ability to scale proven outcomes, those create value that compounds differently. You're building trust and demonstrating results that attract more investment. I mean, chronic disease affects

60% of American adults. Healthcare costs consume 18% of GDP. So the market need is enormous. Enormous. And signal-based medicine addresses that need by moving beyond symptom management. The ecosystem includes AI divisions, consumer health products, and advanced regenerative medicine. It's a complete approach. The portfolio includes multiple companies operating under the same clinical model, right?

They share the signal-based medicine methodology. Each company focuses on different aspects, clinical care, consumer products, AI integration, regenerative therapies, but they all aim to correct dysfunction at the source. So to everyone listening, have you ever wondered why some health care investments promise everything but deliver recurring bills instead of lasting outcomes? Yeah, and here's a quick story. I remember early on hearing about patients who'd been through traditional routes without success, When signal-based medicine restored their function, those patients became advocates. That's when the methodology proved it could scale.

And that's the origin of the fund. Build what works, prove it works, then invite investors to scale it. That build-first mentality is really what sets this apart. Exactly. Most funds search for deals. This fund was created to scale what already works. There's a big difference between a hypothesis and 20 years of clinical validation. So, uh, for accredited investors, the minimum is $250,000. The target is $250 million.

That's institutional scale. It is. And the fund is open for investment now. The messaging emphasizes that this is strategic capital for healthcare transformation, not speculative venture bets. Mm-hmm. Right. Before we wrap, let's touch on the AI first angle.

How does AI fit into the clinical model? AI divisions within the ecosystem help identify biological signals more efficiently, personalized treatment protocols, and scale insights across patient populations. It improves the clinical approach without replacing the human element. So we've established the fund's origins, the signal-based medicine methodology, and the ecosystem structure. What's the takeaway for investors evaluating this? The takeaway is this. You're investing in companies that have already treated tens of thousands of patients,

achieve documented outcomes, and build operational infrastructure. The risk profile is fundamentally different from early stage health care bets. And the impact piece, healing patients instead of managing symptoms, aligns with both returns and mission. Right, impact plus returns, that's the promise. And given the clinical data and the veteran leadership, there's a strong foundation. Thanks for breaking this down. It's a fascinating approach.

build first, fund later. That's how you turn clinical credibility into investment opportunity. Absolutely, and for anyone curious, the transparency around outcomes and infrastructure makes due diligence more straightforward. Appreciate your time today. Until next time, keep asking why the fund exists,

not just what it costs.